Atommap

Executive Summary

Atommap is a San Francisco-based computational drug discovery company founded in 2020 that leverages artificial intelligence and molecular dynamics simulations to design novel therapeutics capable of reprogramming protein function by targeting biomolecular motion. The company’s platform focuses on generating molecular glues and degraders, addressing challenging drug targets that are often considered undruggable by traditional approaches. By combining advanced AI algorithms with physics-based simulations, Atommap aims to accelerate the discovery of small molecules that modulate protein-protein interactions and induce targeted protein degradation, offering a differentiated strategy for treating diseases such as cancer, neurodegenerative disorders, and other conditions driven by aberrant protein dynamics. The company's computational-first approach has the potential to significantly shorten drug development timelines and expand the therapeutic landscape beyond conventional binding-site inhibitors. As a private, early-stage company with no disclosed funding history or valuation, Atommap operates in the highly competitive AI-driven drug discovery space, where several players (e.g., Recursion, Insilico Medicine) have attracted substantial capital. The company's success will hinge on its ability to validate its platform through preclinical studies, secure partnerships with pharmaceutical firms, and attract venture funding to advance its own pipeline. While the technology is promising, Atommap currently lacks public data on lead programs, revenue, or collaborations, making its near-term prospects uncertain. However, the rising interest in targeted protein degradation and AI-enabled drug discovery provides a favorable market tailwind for the company’s growth.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round60% success
• Q1 2027Pharmaceutical Partnership or Licensing Deal40% success
• Q2 2027Preclinical Proof-of-Concept Data for Lead Program50% success